It is Time to “Overweight” DBV Technologies S.A (NASDAQ:DBVT), Barclays Capital Says. Stock May Be Worth $58.00

Share

Why Has Barclays Capital Given DBV Technologies S.A (NASDAQ:DBVT) a $58.00 Price Target

In an analyst research report announced on 3 December, professional analysts at Barclays Capital launched coverage for DBV Technologies S.A (NASDAQ:DBVT) shares. The firm has decided to set a “Overweight” rating along with a $58.00, adding 61.34% to the target.

From a total of 6 analysts covering DBV Technologies (NASDAQ:DBVT) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $59 while the lowest target price is $47. The mean of all analyst targets is $51.33 with a 42.72% above today’s ($35.93) stock price. DBV Technologies was the topic of 5 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. Bank of America initiated shares on October 23 with “Buy” rating. Morgan Stanley initiated DBVT stock in a recent report from September 15 with “Overweight” rating. Finally, Leerink Swann maintained the stock with “Outperform” rating in a report issued on an August 11.

Approximately 132,406 shares of stock traded hands. DBV Technologies SA – ADR (NASDAQ:DBVT) has risen 37.67% since April 30, 2015 and is uptrending. It has outperformed by 37.96% the S&P500.

It is Time to

DBV Technologies SA is a France-based clinical-stage biopharmaceutical firm focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The company has a market cap of $1.66 billion. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It currently has negative earnings. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock.

According to Zacks Investment Research, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.” Get a free copy of the Zacks research report on DBV Technologies SA – ADR (DBVT).

COMMENTS: